Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
28/2 13:55
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items....